ESMO World Congress on Gastrointestinal Cancer | Conference

FOLFOX/Cetuximab Prolonged Survival in Mutation-Free Colorectal Cancer
July 06, 2015

Treatment with FOLFOX plus cetuximab resulted in improved PFS vs FOLFOX alone in patients with metastatic colorectal cancer with “all-RAS” wild-type tumors.

TAS-102 Effective for Wild-Type, Mutant KRAS mCRC
July 06, 2015

A subgroup analysis of the phase III RECOURSE trial has shown that TAS-102 is effective at improving survival in patients with both KRAS wild-type or mutant metastatic colorectal cancer.

CONSIGN, CONCUR Confirm Efficacy of Regorafenib in mCRC
July 06, 2015

Two phase III trials have confirmed the benefit of regorafenib, an oral multikinase inhibitor, in patients with previously treated metastatic colorectal cancer.